Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Amcol International was a global leader in specialty materials and delivery systems, particularly through its Amcol Health & Beauty Solutions division. The company specialized in the development and manufacture of polymer-based delivery systems, such as Microsponge and Poly-Pore, which are designed to enhance the performance of active ingredients in topical pharmaceutical and personal care products. These technologies provide controlled release, improved stability, and reduced irritation for a wide range of dermatological applications. Amcol's delivery systems have been utilized in numerous high-profile products, including the prescription acne treatment Retin-A Micro. In 2014, Amcol was acquired by Minerals Technologies Inc. for approximately $1.7 billion. Today, its life sciences capabilities are integrated into the broader Minerals Technologies portfolio, continuing to serve the global skincare and pharmaceutical markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Amcol.